Effect of non invasive brain stimulation using direct current treatment on auditory hallucinations in schizophrenia

Not Applicable

Completed

• Conditions: Health Condition 1: null- Schizophrenia

• Registration Number: CTRI/2018/02/012061
• Lead Sponsor: ational Institute of Mental health and Neurosciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-10-28
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 34

Inclusion Criteria

1) Diagnosis of schizophrenia / schizophreniform disorder as per DSM criteria (Diagnostic and Statistical Manual for Mental Disorders, American Psychiatric Association); 2) Persistent auditory hallucination despite adequate antipsychotic medication (atleast one antipsychotic trial) with unchanged dose at least for the past 4 weeks. 3) Clinically Significant Auditory Verbal Hallucinations as defined by a structured rating scale for assessing auditory hallucination; 4) Age range: 18 â?? 45 years; 5) Both sexes; 6) Right Handedness and 7) Having satisfactory capacity to consent. 8) Written informed consent.

Exclusion Criteria

1) Features suggestive of psychiatric emergency (for example: suicidal risk, aggression, excitement, catatonia, prolonged nutritional deprivation or any other status requiring intensive clinical care), 2) Any contraindication to HD-tDCS procedure â?? (i) metal in the head, (ii) implanted brain medical devices, (iii) local lesion or injury in the scalp / head, 3) Any concurrent co-morbid psychiatric diagnosis; 4) Pregnancy or post-partum status; 5) Any contraindication for MRI; and 6) Left Handedness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Severity of auditory hallucinations. <br/ ><br>2. Change in the neural correlates involved in auditory hallucinations(Using brain imaging techniques like structural MRI, resting fMRI and DTI) <br/ ><br>Timepoint: Twice. First day (Day 0), before the treatment with HD-tDCS is given. And second on the last day(day 5), after the second session of HD-tDCS treatment is over.

Secondary Outcome Measures

Name	Time	Method
Severity of positive and negative symptomsTimepoint: Twice. First day (Day 0), before the treatment with HD-tDCS is given. And second on the last day(day 5), after the second session of HD-tDCS treatment is over.